Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Breathe Right is a leading global brand specializing in non-pharmacological nasal strips designed to improve breathing by mechanically opening nasal passages. Originally developed by CNS Inc. and launched in 1992, the brand has undergone several ownership changes, including a major acquisition by GlaxoSmithKline in 2006 and its most recent acquisition by Foundation Consumer Healthcare in 2020. The products are primarily used to alleviate nasal congestion caused by colds, allergies, or a deviated septum, and are a popular drug-free solution for reducing snoring. As a Class I medical device, Breathe Right strips utilize a flexible, spring-like band to lift the sides of the nose and widen the nasal valves. The brand maintains a dominant market share in the over-the-counter external nasal dilator category and is widely distributed across retail pharmacies and global markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Breathe Right.